Jakub Michał Lichoń
Research Subjects
Research Interests
Jakub Michał Lichoń has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Mateusz Józef Gołdyn
Podhale Specialist hospital in Nowy Targ Szpitalna 14 34-400, Nowy Targ
8 shared publications - Jakub Pietrucha
Municipal Hospital in Siemianowice Śląskie 1 Maja 9, 41-100 Siemianowice Śląskie, Poland
5 shared publications - Konrad Turczynowski
University Hospital in Kraków Jakubowskiego 2, 30-688 Kraków
5 shared publications - Wojciech Kuna
Zagłębie Oncology Center - Specialist Hospital named after Sz. Starkiewicz in Dąbrowa Górnicza Szpitalna 13, 41-300 Dąbrowa Górnicza
5 shared publications - Paweł Jan Kuna
Beskid Oncology Center - Municipal Hospital of John Paul II in Bielsko-Biała
4 shared publications - Agata Karasiewicz
Otwock County Hospital – Otwock County Health Centre, Otwock, Poland
3 shared publications
Latest Publications
- Open Access
- 12 March 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 88, 69418
Do SGLT2 Inhibitors Affect Skeletal Muscle Mass and Strength? A Systematic Review of Body Composition and Functional Outcomes
Background. Sodium–glucose cotransporter-2 inhibitors (SGLT2i) are widely used in the treatment of type 2 diabetes mellitus, chronic kidney disease, and heart failure. Although these agents promote weight loss and improve cardiometabolic outcomes, concerns have emerged regarding potential reductions in skeletal muscle mass and their impact on physical function. Aim. To review current evidence on the effects of SGLT2 inhibitors on skeletal muscle mass, muscle strength, and functional outcomes. Material and methods. A systematic narrative review of English-language studies published between 2020 and 2026 was conducted. Randomized controlled trials, observational studies, and meta-analyses evaluating body composition and functional performance outcomes during SGLT2 inhibitor therapy were included. Results. SGLT2 inhibitors consistently reduced body weight primarily through fat mass loss, while reductions in lean mass were generally small. Skeletal muscle mass and handgrip strength were largely preserved in middle-aged adults, whereas greater variability was observed in older individuals and patients with chronic kidney disease. Evidence suggests that physical activity and adequate nutrition may mitigate potential muscle loss. Conclusions. SGLT2 inhibitors promote favorable body recomposition with predominantly fat mass reduction and minimal effects on muscle function in most patients. Monitoring muscle health and supporting lifestyle interventions may be beneficial in vulnerable populations.
- 12 March 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 88, 69418
Open AccessDo SGLT2 Inhibitors Affect Skeletal Muscle Mass and Strength? A Systematic Review of Body Composition and Functional Outcomes
Background. Sodium–glucose cotransporter-2 inhibitors (SGLT2i) are widely used in the treatment of type 2 diabetes mellitus, chronic kidney disease, and heart failure. Although these agents promote weight loss and improve cardiometabolic outcomes, concerns have emerged regarding potential reductions in skeletal muscle mass and their impact on physical function. Aim. To review current evidence on the effects of SGLT2 inhibitors on skeletal muscle mass, muscle strength, and functional outcomes. Material and methods. A systematic narrative review of English-language studies published between 2020 and 2026 was conducted. Randomized controlled trials, observational studies, and meta-analyses evaluating body composition and functional performance outcomes during SGLT2 inhibitor therapy were included. Results. SGLT2 inhibitors consistently reduced body weight primarily through fat mass loss, while reductions in lean mass were generally small. Skeletal muscle mass and handgrip strength were largely preserved in middle-aged adults, whereas greater variability was observed in older individuals and patients with chronic kidney disease. Evidence suggests that physical activity and adequate nutrition may mitigate potential muscle loss. Conclusions. SGLT2 inhibitors promote favorable body recomposition with predominantly fat mass reduction and minimal effects on muscle function in most patients. Monitoring muscle health and supporting lifestyle interventions may be beneficial in vulnerable populations.
- Open Access
- 2 March 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (1(49))
MULTIDISCIPLINARY MANAGEMENT OF AWAKE AND SLEEP BRUXISM: A LITERATURE REVIEW
Introduction: Bruxism is currently understood as a range of jaw muscle activities and teeth contact that occur during sleep and/or wakefulness. Awake bruxism can be distinguished from sleep bruxism based on differences in etiology, comorbidities, and the spectrum of muscle activity and clinical manifestations. Although the exact cause of bruxism remains unclear, it is considered to be multifactorial. This article aims to highlight both awake and bruxism and explore various approaches to their management. Aim of the Study: The aim of this article is to review current knowledge on awake and sleep bruxism and increase awareness of its multidisciplinary management. Materials and Methods: A literature review was conducted using the PubMed and Google Scholar databases. The following keywords were used in various combinations: "bruxism," "awake," "sleep" "management," "treatment," and "oral health." Fourty four relevant articles published between 2001 and 2025 were selected for analysis. Results: The most common current approaches to managing awake and sleep bruxism include occlusal splints, mandibular advancement devices, cognitive-behavioral therapy (CBT), biofeedback therapy, mindfulness techniques, self-awareness and self-regulation strategies, physical therapy (such as physiotherapy, exercise, and dry needling), botulinum toxin injections, and non-steroidal anti-inflammatory drugs (NSAIDs) for pain exacerbation. Conclusion: Bruxism and its associated symptoms can significantly affect patients' quality of life. Early identification and appropriate management can help reduce facial muscle soreness, headaches, and general fatigue and pathological tooth wear.
- 2 March 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (1(49))
Open AccessMULTIDISCIPLINARY MANAGEMENT OF AWAKE AND SLEEP BRUXISM: A LITERATURE REVIEW
Introduction: Bruxism is currently understood as a range of jaw muscle activities and teeth contact that occur during sleep and/or wakefulness. Awake bruxism can be distinguished from sleep bruxism based on differences in etiology, comorbidities, and the spectrum of muscle activity and clinical manifestations. Although the exact cause of bruxism remains unclear, it is considered to be multifactorial. This article aims to highlight both awake and bruxism and explore various approaches to their management. Aim of the Study: The aim of this article is to review current knowledge on awake and sleep bruxism and increase awareness of its multidisciplinary management. Materials and Methods: A literature review was conducted using the PubMed and Google Scholar databases. The following keywords were used in various combinations: "bruxism," "awake," "sleep" "management," "treatment," and "oral health." Fourty four relevant articles published between 2001 and 2025 were selected for analysis. Results: The most common current approaches to managing awake and sleep bruxism include occlusal splints, mandibular advancement devices, cognitive-behavioral therapy (CBT), biofeedback therapy, mindfulness techniques, self-awareness and self-regulation strategies, physical therapy (such as physiotherapy, exercise, and dry needling), botulinum toxin injections, and non-steroidal anti-inflammatory drugs (NSAIDs) for pain exacerbation. Conclusion: Bruxism and its associated symptoms can significantly affect patients' quality of life. Early identification and appropriate management can help reduce facial muscle soreness, headaches, and general fatigue and pathological tooth wear.
- Open Access
- 24 February 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 1 (1(49))
ARTIFICIAL INTELLIGENCE IN ANESTHETIC DRUG DELIVERY AND HEMODYNAMIC CONTROL: CLOSED-LOOP SYSTEMS, PREDICTION ALGORITHMS, AND A PRACTICAL IMPLEMENTATION APPROACH
Modern anesthesia is a high-frequency control problem: clinicians must continuously titrate hypnotics, opioids, fluids, and vasopressors to achieve adequate hypnosis/analgesia while avoiding hemodynamic instability and downstream organ injury. Artificial intelligence (AI), machine learning, and classical control engineering are increasingly embedded in perioperative monitors and drug delivery platforms, enabling decision support and closed-loop control. Randomized trials and meta-analyses indicate that closed-loop systems for hypnosis (typically processed EEG targets such as BIS) improve time-in-target and reduce overshoot/undershoot compared with manual titration. Multi-variable systems that co-manage hypnosis, analgesia, and fluids are feasible and may improve short-term recovery outcomes in selected settings. On the hemodynamic side, intraoperative hypotension is common and associated with myocardial and kidney injury, AI-based early warning systems using arterial waveforms can predict hypotension minutes before onset and, when paired with treatment protocols, may reduce hypotension burden in some trials. Closed-loop vasopressor and fluid systems improve protocol adherence and reduce hypotension in perioperative and early postoperative care. AI-enabled decision support and closed-loop controllers can improve stability of anesthesia and blood pressure management, but they should be implemented as supervised systems with clear safety constraints, manual override, and ongoing performance monitoring. Future multicenter trials should prioritize patient-centered outcomes, external validation, and transparent reporting.
- 24 February 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 1 (1(49))
Open AccessARTIFICIAL INTELLIGENCE IN ANESTHETIC DRUG DELIVERY AND HEMODYNAMIC CONTROL: CLOSED-LOOP SYSTEMS, PREDICTION ALGORITHMS, AND A PRACTICAL IMPLEMENTATION APPROACH
Modern anesthesia is a high-frequency control problem: clinicians must continuously titrate hypnotics, opioids, fluids, and vasopressors to achieve adequate hypnosis/analgesia while avoiding hemodynamic instability and downstream organ injury. Artificial intelligence (AI), machine learning, and classical control engineering are increasingly embedded in perioperative monitors and drug delivery platforms, enabling decision support and closed-loop control. Randomized trials and meta-analyses indicate that closed-loop systems for hypnosis (typically processed EEG targets such as BIS) improve time-in-target and reduce overshoot/undershoot compared with manual titration. Multi-variable systems that co-manage hypnosis, analgesia, and fluids are feasible and may improve short-term recovery outcomes in selected settings. On the hemodynamic side, intraoperative hypotension is common and associated with myocardial and kidney injury, AI-based early warning systems using arterial waveforms can predict hypotension minutes before onset and, when paired with treatment protocols, may reduce hypotension burden in some trials. Closed-loop vasopressor and fluid systems improve protocol adherence and reduce hypotension in perioperative and early postoperative care. AI-enabled decision support and closed-loop controllers can improve stability of anesthesia and blood pressure management, but they should be implemented as supervised systems with clear safety constraints, manual override, and ongoing performance monitoring. Future multicenter trials should prioritize patient-centered outcomes, external validation, and transparent reporting.
- Open Access
- 20 February 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 1 (1(49))
CARDIOVASCULAR TOXICITY OF ANABOLIC-ANDROGENIC STEROIDS IN RECREATIONAL ATHLETES: MECHANISMS, CLINICAL PHENOTYPES, AND A PRACTICAL DIAGNOSTIC APPROACH
Non-medical use of anabolic-androgenic steroids (AAS) has expanded beyond elite sports and is common among recreational strength trainees. Chronic supraphysiologic exposure is associated with adverse cardiovascular (CV) remodeling, accelerated atherosclerosis, and excess mortality. This review synthesizes evidence on AAS-associated CV toxicity and proposes a pragmatic diagnostic approach. Current data describe distinct clinical features in users: (i) often reversible cardiometabolic disturbances (dyslipidaemia, hypertension), (ii) structural remodeling, notably concentric left ventricular hypertrophy, (iii) impaired global longitudinal strain that can persist years after cessation, and (iv) premature coronary plaque burden linked to cumulative lifetime exposure. Furthermore, cardiac PET/CT studies indicate persistent coronary microvascular dysfunction, while registry cohorts confirm increased CV disease rates. Consequently, AAS use should be considered a major, under-recognized CV risk factor. We propose a phenotype-based assessment integrating non-judgmental history-taking, athlete-specific ECG interpretation, echocardiography with strain, and selective use of CMR and CCTA. Management should prioritize cessation support, harm reduction, and guideline-directed therapy tailored to the specific clinical phenotype (e.g., cardiomyopathy or coronary disease).
- 20 February 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 1 (1(49))
Open AccessCARDIOVASCULAR TOXICITY OF ANABOLIC-ANDROGENIC STEROIDS IN RECREATIONAL ATHLETES: MECHANISMS, CLINICAL PHENOTYPES, AND A PRACTICAL DIAGNOSTIC APPROACH
Non-medical use of anabolic-androgenic steroids (AAS) has expanded beyond elite sports and is common among recreational strength trainees. Chronic supraphysiologic exposure is associated with adverse cardiovascular (CV) remodeling, accelerated atherosclerosis, and excess mortality. This review synthesizes evidence on AAS-associated CV toxicity and proposes a pragmatic diagnostic approach. Current data describe distinct clinical features in users: (i) often reversible cardiometabolic disturbances (dyslipidaemia, hypertension), (ii) structural remodeling, notably concentric left ventricular hypertrophy, (iii) impaired global longitudinal strain that can persist years after cessation, and (iv) premature coronary plaque burden linked to cumulative lifetime exposure. Furthermore, cardiac PET/CT studies indicate persistent coronary microvascular dysfunction, while registry cohorts confirm increased CV disease rates. Consequently, AAS use should be considered a major, under-recognized CV risk factor. We propose a phenotype-based assessment integrating non-judgmental history-taking, athlete-specific ECG interpretation, echocardiography with strain, and selective use of CMR and CCTA. Management should prioritize cessation support, harm reduction, and guideline-directed therapy tailored to the specific clinical phenotype (e.g., cardiomyopathy or coronary disease).
- Open Access
- 17 February 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 51
Impact of GLP-1 Receptor Agonists on Body Composition and Physical Performance in Patients with Obesity: A Comprehensive Review of Current Research
Background.GLP-1 receptor agonists (GLP-1RAs) are central to obesity pharmacotherapy, producing substantial and sustained weight loss in randomized trials, with additional cardiometabolic benefits. Growing attention concerns their effects on body composition, particularly fat versus lean mass loss, and potential impacts on skeletal muscle function and physical performance. These outcomes are highly relevant to sports medicine and rehabilitation, where muscle preservation is crucial. Aim.To review evidence on the effects of GLP-1RAs on body composition and physical performance in adults with obesity, focusing on fat mass, lean mass and populations at risk of muscle-related adverse effects. Materials and methods.Narrative review of 30 PubMed-indexed studies (2015–2026), including RCTs, DXA substudies and reviews of liraglutide, semaglutide and tirzepatide in adults with overweight/obesity. Results.GLP-1RAs consistently reduced body weight and fat mass, with 15–40% of weight loss attributable to lean mass reduction. Semaglutide improved physical function and exercise tolerance in obesity-related functional impairment and HFpEF, while potential sarcopenic effects were reported in older adults and those with low baseline muscle mass. Reviews highlight heterogeneity of lean mass responses and the importance of lifestyle interventions. Conclusions.GLP-1RAs induce major fat loss but are associated with clinically relevant lean mass loss. Combining pharmacotherapy with exercise and nutrition is essential to optimize body composition and physical performance.
- 17 February 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 51
Open AccessImpact of GLP-1 Receptor Agonists on Body Composition and Physical Performance in Patients with Obesity: A Comprehensive Review of Current Research
Background.GLP-1 receptor agonists (GLP-1RAs) are central to obesity pharmacotherapy, producing substantial and sustained weight loss in randomized trials, with additional cardiometabolic benefits. Growing attention concerns their effects on body composition, particularly fat versus lean mass loss, and potential impacts on skeletal muscle function and physical performance. These outcomes are highly relevant to sports medicine and rehabilitation, where muscle preservation is crucial. Aim.To review evidence on the effects of GLP-1RAs on body composition and physical performance in adults with obesity, focusing on fat mass, lean mass and populations at risk of muscle-related adverse effects. Materials and methods.Narrative review of 30 PubMed-indexed studies (2015–2026), including RCTs, DXA substudies and reviews of liraglutide, semaglutide and tirzepatide in adults with overweight/obesity. Results.GLP-1RAs consistently reduced body weight and fat mass, with 15–40% of weight loss attributable to lean mass reduction. Semaglutide improved physical function and exercise tolerance in obesity-related functional impairment and HFpEF, while potential sarcopenic effects were reported in older adults and those with low baseline muscle mass. Reviews highlight heterogeneity of lean mass responses and the importance of lifestyle interventions. Conclusions.GLP-1RAs induce major fat loss but are associated with clinically relevant lean mass loss. Combining pharmacotherapy with exercise and nutrition is essential to optimize body composition and physical performance.
- Open Access
- 3 February 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 51, 68152
Application of Machine Learning Algorithms in Automatic Anesthetic Drug Delivery Systems: A literature review
The dynamic advancements in artificial intelligence are enabling the integration of machine learning into medical practice. A significant challenge in modern anesthesiology is the need for precise, continuous adjustment of anesthetic drug doses in response to the patient's rapidly changing physiological state. Traditional manual methods of drug delivery often result in excessive variability in the depth of anesthesia and hemodynamic stability. Utilizing machine learning algorithms represents a modern, promising approach designed to enhance the overall quality and safety of anesthetic care. Aim of the study: The objective of this study is to review the current state of knowledge concerning machine algorithms in automated anesthetic drug delivery systems and to compare these with conventional administration methods, evaluating the benefits and limitations of each approach. Materials and methods: A review of selected literature in the PubMed, Google Scholar database was conducted, using the following keywords: “anesthetic drugs”, “machine learning”, “closed-loop system” “artificial intelligence” Conclusions: The review demonstrates that Machine Learning-driven Closed-Loop Anesthesia Delivery Systems (CLADS) offer superior stability of anesthetic depth and hemodynamic control compared to manual administration. The implementation of AI allows for the personalization of therapy and a significant reduction in drug and gas wastage, supporting the "Green Anesthesia" initiative. Furthermore, automation contributes to better long-term outcomes, such as reduced incidence of postoperative delirium and cognitive dysfunction. However, despite high autonomy, the "human-in-the-loop" paradigm remains essential due to technical artifacts and unforeseen surgical events. Future research should focus on regulatory standardization and the integration of multi-loop systems managing hypnosis, analgesia, and neuromuscular blockade simultaneously.
- 3 February 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 51, 68152
Open AccessApplication of Machine Learning Algorithms in Automatic Anesthetic Drug Delivery Systems: A literature review
The dynamic advancements in artificial intelligence are enabling the integration of machine learning into medical practice. A significant challenge in modern anesthesiology is the need for precise, continuous adjustment of anesthetic drug doses in response to the patient's rapidly changing physiological state. Traditional manual methods of drug delivery often result in excessive variability in the depth of anesthesia and hemodynamic stability. Utilizing machine learning algorithms represents a modern, promising approach designed to enhance the overall quality and safety of anesthetic care. Aim of the study: The objective of this study is to review the current state of knowledge concerning machine algorithms in automated anesthetic drug delivery systems and to compare these with conventional administration methods, evaluating the benefits and limitations of each approach. Materials and methods: A review of selected literature in the PubMed, Google Scholar database was conducted, using the following keywords: “anesthetic drugs”, “machine learning”, “closed-loop system” “artificial intelligence” Conclusions: The review demonstrates that Machine Learning-driven Closed-Loop Anesthesia Delivery Systems (CLADS) offer superior stability of anesthetic depth and hemodynamic control compared to manual administration. The implementation of AI allows for the personalization of therapy and a significant reduction in drug and gas wastage, supporting the "Green Anesthesia" initiative. Furthermore, automation contributes to better long-term outcomes, such as reduced incidence of postoperative delirium and cognitive dysfunction. However, despite high autonomy, the "human-in-the-loop" paradigm remains essential due to technical artifacts and unforeseen surgical events. Future research should focus on regulatory standardization and the integration of multi-loop systems managing hypnosis, analgesia, and neuromuscular blockade simultaneously.
- Open Access
- 18 January 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 49, 67622
Evaluation of the Efficacy and Safety of Thalamotomy and Pallidotomy Using Focused Ultrasound (FUS) in the Treatment of Essential Tremor and Parkinson’s Disease: A Literature Review
Introduction: Parkinson’s Disease (PD) and Essential Tremor (ET) are the two most prevalent movement disorders, with tremor being a core, often drug-refractory, motor feature. While traditional surgical treatments like Deep Brain Stimulation (DBS) and Radiofrequency (RF) ablation are effective, they are invasive and carry inherent risks such as hemorrhage and infection, necessitating craniotomy. This reality drives the need for less invasive therapeutic options for patients with advanced, medication-refractory symptoms and motor fluctuations. Aim: The aim of this systematic review is to assess the clinical efficacy and safety profile of Thalamotomy and Pallidotomy performed using Magnetic Resonance-Guided Focused Ultrasound (MRgFUS) technology in the treatment of Essential Tremor and Parkinson’s Disease. Review methods: A comprehensive analysis of research papers available on PubMed and Google Scholar was conducted using keywords: Focused Ultrasound (FUS), Essential Tremor (ET), Parkinson's Disease (PD), Thalamotomy, Pallidotomy, MRgFUS. Conclusion: MRgFUS-guided thalamotomy (VIM) and pallidotomy (GPi) constitute a breakthrough, non-invasive alternative to traditional surgical ablations. The technology demonstrates high and durable efficacy, achieving a 47% reduction in ET tremor and a 39,1% reduction in PD motor symptoms (UPDRS III), comparable to invasive standards. Crucially, MRgFUS offers a favorable safety profile by eliminating the risk of surgical bleeding and infection while providing real-time lesion monitoring. However, a key limitation remains the requirement for an adequate Skull Density Ratio (SDR), excluding some clinically eligible patients. Further long-term, prospective studies are required to fully establish its role.
- 18 January 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 49, 67622
Open AccessEvaluation of the Efficacy and Safety of Thalamotomy and Pallidotomy Using Focused Ultrasound (FUS) in the Treatment of Essential Tremor and Parkinson’s Disease: A Literature Review
Introduction: Parkinson’s Disease (PD) and Essential Tremor (ET) are the two most prevalent movement disorders, with tremor being a core, often drug-refractory, motor feature. While traditional surgical treatments like Deep Brain Stimulation (DBS) and Radiofrequency (RF) ablation are effective, they are invasive and carry inherent risks such as hemorrhage and infection, necessitating craniotomy. This reality drives the need for less invasive therapeutic options for patients with advanced, medication-refractory symptoms and motor fluctuations. Aim: The aim of this systematic review is to assess the clinical efficacy and safety profile of Thalamotomy and Pallidotomy performed using Magnetic Resonance-Guided Focused Ultrasound (MRgFUS) technology in the treatment of Essential Tremor and Parkinson’s Disease. Review methods: A comprehensive analysis of research papers available on PubMed and Google Scholar was conducted using keywords: Focused Ultrasound (FUS), Essential Tremor (ET), Parkinson's Disease (PD), Thalamotomy, Pallidotomy, MRgFUS. Conclusion: MRgFUS-guided thalamotomy (VIM) and pallidotomy (GPi) constitute a breakthrough, non-invasive alternative to traditional surgical ablations. The technology demonstrates high and durable efficacy, achieving a 47% reduction in ET tremor and a 39,1% reduction in PD motor symptoms (UPDRS III), comparable to invasive standards. Crucially, MRgFUS offers a favorable safety profile by eliminating the risk of surgical bleeding and infection while providing real-time lesion monitoring. However, a key limitation remains the requirement for an adequate Skull Density Ratio (SDR), excluding some clinically eligible patients. Further long-term, prospective studies are required to fully establish its role.
- Open Access
- 18 January 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 49, 67601
Modern pharmacological strategies in the treatment of Drug-Resistant Epilepsy: evaluation of efficacy and safety: a review
Drug-resistant epilepsy (DRE) is a neurological condition, defined as a failure to make the patient seizure free, after the use of two tolerated, appropriately chosen antiepileptic drugs (AED). Although there is an increasing number of available antiepileptic drugs, it is estimated that pharmacotherapy remains ineffective in approximately 30% of patients. Drug-resistant epilepsy is considered as one of the greatest challenges in modern neurology that affects millions of patients worldwide, who do not respond to standard treatments. Even though epilepsy is one of the most common neurological diseases, with a global total of 50 million people suffering from the condition, treatment of its resistant forms remains complicated and often ineffective. Chronic epileptic seizures can cause serious health problems, limiting patients' mobility, affecting quality of life and increasing the risk of emotional disorders such as depression and anxiety. In response to this challenge, the development of modern drugs for drug-resistant epilepsy has become a medical priority. In recent years, there has been growing interest in new medications such as Cenobamate, Fenfluramine and Cannabidiol, which have different mechanisms of action and promising results in reducing the seizure frequency. Before diagnosing DRE, it is essential to exclude the pseudo-resistance, which may result from different factors such as inadequate doses of medicine, choosing the incorrect medications, or patient-related errors (poor compliance).
- 18 January 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 49, 67601
Open AccessModern pharmacological strategies in the treatment of Drug-Resistant Epilepsy: evaluation of efficacy and safety: a review
Drug-resistant epilepsy (DRE) is a neurological condition, defined as a failure to make the patient seizure free, after the use of two tolerated, appropriately chosen antiepileptic drugs (AED). Although there is an increasing number of available antiepileptic drugs, it is estimated that pharmacotherapy remains ineffective in approximately 30% of patients. Drug-resistant epilepsy is considered as one of the greatest challenges in modern neurology that affects millions of patients worldwide, who do not respond to standard treatments. Even though epilepsy is one of the most common neurological diseases, with a global total of 50 million people suffering from the condition, treatment of its resistant forms remains complicated and often ineffective. Chronic epileptic seizures can cause serious health problems, limiting patients' mobility, affecting quality of life and increasing the risk of emotional disorders such as depression and anxiety. In response to this challenge, the development of modern drugs for drug-resistant epilepsy has become a medical priority. In recent years, there has been growing interest in new medications such as Cenobamate, Fenfluramine and Cannabidiol, which have different mechanisms of action and promising results in reducing the seizure frequency. Before diagnosing DRE, it is essential to exclude the pseudo-resistance, which may result from different factors such as inadequate doses of medicine, choosing the incorrect medications, or patient-related errors (poor compliance).